A number of systematic reviews addressing breast cancer risk associated with HRT following RRBSO in BRCA1/2 mutation carriers have been published (Siyam et al. 2017; Birrer et al. 2018; Gordhandas et al. 2019; Vermeulen et al. 2019; Gaba and Manchanda 2020). The gene discussed is BRCA1; the disease is breast cancer.